Loading...
OTCM
GBLP
Market cap20mUSD
Nov 03, Last price  
0.05USD
Name

Global Pharmatech Inc

Chart & Performance

D1W1MN
OTCM:GBLP chart
P/E
P/S
66.78
EPS
Div Yield, %
Shrs. gr., 5y
79.77%
Rev. gr., 5y
-33.42%
Revenues
311k
+368.39%
1,555,6703,085,1752,375,5112,819,090058,58566,375310,895
Net income
-68k
L-51.10%
310,085200,695-1,234,391-2,445,204-113,314-21,004-138,499-67,728
CFO
15k
P
1,168,982-1,860,329261,772-383,938-62,638391,443-199,26814,907

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Global Pharmatech, Inc. engages in the research, production, and development of herbal medicine, bio-medicine, chemical medicine, traditional chinese medicine, and dietary supplements primarily in China. The company's principal product line consists of XS CAPSULE (XIN-SHU) for the treatment of angina and other coronary disease; JUTAI SOFT CAPSULE, a dietary supplement; QINGXUAN ANTI-HYPERTENSION TABLET, an over-the-counter drug product indicated for the treatment of hypertension and high serum cholesterol level; and YANREQING TABLET for the treatment of inflammation. It also manufactures and sells other proprietary drugs, generics, and dietary supplements used to treat symptoms ranging from headaches, coughing, and dry mouth to infections, and numbness of limbs. The company markets its products through distributors, such as wholesale companies and chain store representatives, as well as through its sales force. Global Pharmatech, Inc. was founded in 2001 and is based in Changchun, China.
IPO date
May 12, 2006
Employees
217
Domiciled in
CN
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFY
2024‑122023‑122022‑122021‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT